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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.016As I was debating and reflecting on what I would say today, Ithought about my own personal experiences in cardiothoracicsurgery and how so much has changed from the time I was a farmboy in North Carolina to becoming a cardiothoracic surgeon andnow president of The Western Thoracic Surgical Association. Ifirst recognize the great opportunities this wonderful profession
has given me. For me, this was the American dream. Believing in this promise, I
refuse to fall victim to the current era of despair in our profession: the complaints
of reimbursement being too low, cardiologists taking all our business away, HMOs
dictating patient care, our graduates unable to find jobs, and some of our colleagues
believing our specialty has seen its golden years come and gone. All of these
complaints do have some element of validity, but to effect change and alter the
current circumstances, we have to understand more fully the sequence of events
leading to these concerns. First, I accept the concept of change and know the only
constancy is change. Therefore, I do not give into the psychology of the golden
years of cardiothoracic surgery. Instead, I believe in the concept of cardiothoracic
surgery as an evolving discipline and as such have much to look forward to. These
times bring to mind a quotation from Henry Wadsworth Longfellow: “Look not
mournfully into the past. It comes not back again. Wisely improve the present. It is
thine. Go forth to meet the shadowy future, without fear, and with a manly heart.”
As an evolving discipline, we need to understand the acrimony. Is the golden age
past? The short answer is no. As a specialty, we are cardiac, thoracic, congenital,
and vascular surgeons. Cardiac surgeons have to be careful not to imply the entire
specialty is in trouble because coronary artery bypass surgery is down 25%. In fact,
as I talk to my colleagues who perform thoracic surgery, it might be one of the most
exciting times in nearly 80 years. Thoracic surgery has emerged from a palliative
discipline of draining empyemas and cancer resections into a better understanding
of the biology of lung and esophageal tumors. Resective therapy with careful staging
and, if needed, adjuvant therapy offers cure to patients with lung cancer. Lung
transplantation has developed from an experimental procedure in 1986 to an
accepted form of therapy for end-stage lung disease. Last year, nearly 1100 lung
transplantations were performed in the United States.1 The 1-year survival after
transplantation has increased from 60% in 1986 to as high as 90% in selected centers
in the year 2003. These improved results are due to better immunosuppression and
increased recognition and treatment of the various multifactorial causes of bronchi-
olitis obliterans. For example, this dreaded complication has been reduced by noting
the relationship with gastroesophageal reflux and performing antireflux procedures.
Living donor lung transplantations are being done with increasing frequency.
In 2003, at The American Association for Thoracic Surgery meeting in Toronto,
we reported our 10-year experience with 128 lobar lung transplantations. Our
conclusion was that this procedure is an ideal operation for children and young
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bronchiolitis obliterans syndrome was half that of cadaveric
lung transplantation. Lobar transplantation has developed
from an experimental procedure beginning in 1990 to an
accepted therapy for critically ill patients with end-stage
lung disease.
These are a few examples of why thoracic surgery is very
active and exciting. A barometer of this excitement is mea-
sured by the increasing numbers of entering thoracic resi-
dents who are choosing thoracic surgery as their subspe-
cialty. Another discipline that has gained excitement and
momentum over the past 20 years has been surgery for
congenital heart disease. This evolution has progressed
from palliative procedures, such as the Blalock-Taussig
shunt for tetralogy of Fallot, to complete repair in the
neonatal period. Whereas children would present with cya-
notic heart disease and receive palliative procedures, now
these neonates undergo total repair. This therapy limits the
number of operations infants are exposed to and results in
better outcomes without the interval mortality between pal-
liation and corrective surgery. Hypoplastic left heart syn-
drome was a diagnosis with 100% mortality. Today these
infants are undergoing first-stage palliation with greater
than 85% success.2 This tremendous progress has been
made because of a few pioneers, such as Bill Norwood, not
succumbing to risks and criticism. Instead he took the
clinical problems as challenges and spent 10 to 15 years
perfecting an operation that now saves hundreds of new-
borns. These pioneers did not accept the status quo but
embraced the need for change and became part of the
changing influence. They took lesions with poor outcomes
and tried to make a difference, although success did not
come quickly. Today I challenge all of us to accept this
pioneering spirit as we approach our current challenges. In
the short span of 20 years, we have taken a lesion (hypo-
plastic left heart) from a hopeless condition to now having
surgical outcomes with greater than 80% survival.3
These few examples are representative of the exciting
changes that have occurred in other disciplines within our
specialty. If we try to understand why there is pessimism
today, we need to understand the scope of the problems.
Adult cardiac surgery has been prolific in terms of the
number of patients treated and the number of surgeons
rendering their care. Therefore, when a major change occurs
in this discipline, its reverberations are felt throughout the
specialty. As a consequence, the specialty as a whole now
has a problem rather than a segment of the specialty. If we
analyze the problem within adult cardiac surgery, do we
conclude that it is all of adult cardiac surgery or just coro-
nary bypass surgery? Over the past 20 years, coronary
bypass surgery defined the practice of adult cardiac surgery.
Coronary bypass operations comprised 80% to 90% of most
cardiac surgeons’ activity and therefore defined the value
484 The Journal of Thoracic and Cardiovascular Surgery ● Marmost surgeons placed on their practice. Simply put, a car-
diac surgeon was an adult cardiac surgeon who performed
“X” number of bypass operations with “0” mortality. If this
is the yardstick by which we measured our specialty, then it
is easy for all of us today to understand the sense of
frustration that has developed.
Rather than becoming frustrated and resentful of change,
we need now, more than ever, to take on the pioneering
spirit and be part of the evolution of our discipline. The
indicator of needed change has been the downturn in the
number of patients referred for coronary bypass operations.
During the past year, the number of coronary artery bypass
grafting (CABG) operations is down approximately 25%.
This occurred as a result of many factors. Cardiologists have
become successful in opening coronary blockages with bal-
loons, stents, and now with improved drug-eluting stents.
As cardiothoracic surgeons, we have not accurately an-
swered the question of whether these procedures are better
for the patient. Patients certainly like the concept of not
having a large incision down the center of the chest. The
patient keeps coming back for repeated procedures. It is
almost as though the results of these stenting and balloon
angioplasty procedures do not matter. We need to ask our-
selves why this continues, particularly in patients with pre-
dictably poor outcomes.
I believe one answer is that we have totally capitulated
our responsibility to our patients by not making them more
aware of the alternatives. We have been too concerned
about the business of our specialty and not upsetting the
referring cardiologist. We accepted the 20% to 30% stent
restenosis rate by not being more critical of these results.
We are, through our silence, in agreement with this therapy,
and the patients do not know better. We complain about not
being held with the same regard as in the past. If we are
going to regain self respect as a discipline, we have to stop
behaving as technicians performing surgical procedures.
We have to become physicians again; we have to look for
better ways to treat our patients’ problems. We have to
persuade the cardiologist to look at cooperative trials com-
paring, for example, bypass surgery versus stenting in pa-
tients with 3-vessel disease and diminished ventricular func-
tion. A study from the Cleveland Clinic that looked at these
2 groups was reported in the Wall Street Journal in May
2004.4 The results confirmed that in the high-risk group, the
stented patients had 2.5 times the mortality seen in those
patients having bypass surgery. The high-risk group was
defined by low ejection fraction (40%), multiple-vessel
disease, and diabetes. This study, now published in Circu-
lation,5 is the first comparison in the past 5 years in which
surgeons and cardiologists were willing to look at their data.
The results confirmed what we have surmised. But until
now, no group was willing to compare the data. It will take
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correct patient care algorithm for the best outcomes.
Information and publications regarding our surgical out-
comes are essential, but this is only one piece of the puzzle.
We still have to understand that patients would prefer to
have a catheter-based treatment rather than a huge surgical
scar. How do we overcome this huge hurdle? I believe there
are 2 ways we can approach this dilemma: results and
technology. We have to continually assess our results, com-
paring them with outcomes that are medically produced in
an unbiased fashion. We have to be willing to inform the
patient of these results. This might represent reporting in
less conventional medical publications, such as the Wall
Street Journal. As editors of journals, we are aware of the
impact factor. I would suggest that the impact factor of the
Wall Street Journal article was far greater in terms of
information to the patient than the same article just pub-
lished in Circulation.
We now have patients coming to our office inquiring
about the results and wanting to know more. With public
communication, we can go directly to the patient and have
the opportunity to explain treatment options. This has the
much desired effect of circumventing the gatekeeper, in this
case the cardiologist. I am not advocating a confrontation
with our colleagues. We simply need a more level playing
field. Other ways of making the patient more aware of
treatment choices are public speaking and Internet access.
The next step in our evolution will involve better tech-
nology that allows truly minimally invasive procedures.
Patients do not want large incisions. As surgeons, we have
to accept and try to improve our minimally invasive skills.
We have to exhibit restraint and investigate methods to
which we were not exposed during our surgical residency.
Coronary bypass surgery might have been the siren song
that lulled us into complacency. For more than 20 years, we
had no reason to change because the number of cases
continued to grow and the results improved, with mortality
and morbidity rates reaching 1% to 2%. We made the
mistake of assuming the patients were seeking our proce-
dures because of these outcomes. We failed to recognize the
work of the cardiologist. We had become content with our
procedure while cardiologists’ continued to improve their
therapy for coronary disease. Angioplasty and the early
stents had high restenosis rates. This did not deter their
pursuit of better stents. Now we have drug-eluting stents
with the promise of a less than 10% restenosis rate.6
Our rebuttal during this time was mostly complaining.
During this time, we have failed our patients because we
have not continued to challenge ourselves and improve our
procedures. We need to begin by offering minimally inva-
sive revascularization with arterial grafts. The fright of the
patient over the sternotomy can be partially overcome by
small, less-invasive thoracotomy incisions. With arterial
The Journal of Thoracigrafts, we can tell our patients with confidence of superior
results compared with those achieved with stents. As sur-
geons, we can tell the patient about the restenosis rate and
the effect of taking anticoagulants to keep the stents patent.
Although the restenosis rate is low, the uncertainty of this
therapy has to be made clear to the patient. For example, if
your patient is traveling in some other part of the nation or
world, what happens when he or she gets chest pain? Does
this patient call the nearest emergency department when he
or she has chest pain, or does the patient take antacids and
hope the pain is caused by bad pizza? These potential
scenarios have not been explained. With bypass operations
and small incisions, we can give our patients a more durable
option.
Change and evolution are often difficult to embrace.
However, if we accept that change is needed and become
the mediators of that change, it becomes a part of our
evolving specialty. There are numerous examples of this.
Robotic assisted heart surgery is in its infancy. Whether you
choose to embrace the technology or not, it cannot be
ignored. Patients are exploring their options. When we first
explored robotic assisted mitral valve surgery at the Uni-
versity of Southern California (USC), I was sure there
would be a learning curve and that the operation that nor-
mally takes 2 to 3 hours would take twice as long. Then you
ask yourself, “Why perform the surgery robotically?” I
believe mitral valve surgery done minimally invasively is
better for the patient. In my hands the robot made this
minimally invasive procedure easier, more precise, and
therefore a more durable repair for the patient. Since the
initiation of robotic assisted mitral repair, we have com-
pleted 50 cases with excellent results. In addition, we have
re-explored the insertion of polytetrafluoroethylene chords
rather than leaflet resection and found the results compara-
ble with those after resections and taking less time. Saving
time means less time spent on cardiopulmonary bypass,
which is good for the patient. The result for the patient is a
small (4-6 cm) incision, fewer days in the hospital, quicker
recovery time, and fewer days missed from work.
These are the reasons as cardiothoracic surgeons we have
to explore new methods to better treat our patients. With
these steady advances, we will regain the respect of our
colleagues. Our patients will once again request and receive
choices of treatment options based on evidence-based med-
icine rather than treatment based on who encountered the
patient first.
Another challenge we face as cardiothoracic surgeons is
the temptation to embrace all technology before it has been
proved efficacious. This temptation is spurred by the desire
to increase our practice during a time of a decreasing
number of cases, the desire to be seen as on the leading
edge, and last, the attempt to improve our marketing strat-
c and Cardiovascular Surgery ● Volume 129, Number 3 485
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fail.
For example, approximately 5 years ago, off-pump
CABG (OPCABG) was touted as the safest method of
coronary revascularization. The claims were of fewer
strokes, less blood use, fewer days in the hospital, and
decreased costs. The scientific data to support these claims
have been lacking. However, in a meta-analysis, Parolari
and colleagues7 reviewed 9 studies with matched selection
criteria. There were 558 patients in the routine CABG group
and 532 in the OPCABG group. The composite end point
consisted of death, stroke, and myocardial infarction. No
advantage could be demonstrated by use of one technique
over the other (Table 1). The problem with the study was the
rather short-term follow-up.
Another end point examined by Khan and associates8
was graft patency. With 80% of patients undergoing
angiograms at 3 months, the patency rate in the CABG
group was 98% compared with 88% in the OPCABG
group. With the purported advantages not being realized,
the overall rate of OPCABG has leveled off at approxi-
mately 20% (Table 2).
This technology, although touted as a breakthrough, did
not fulfill surgeons’ expectations. Looking back, this might
have been predicted. The OPCABG operation is much more
difficult to perform. Rather than a motionless field, the
surgeon once again is operating on a beating heart, similar
to what was done in the early 1970s. The technology had
regressed in hopes of avoiding the heart-lung machine and
its complications. What we failed to factor in was the
requirement for enhanced technical performance by the
surgeon needed for OPCABG. In addition, the heart-lung
machine has become safer with membrane oxygenators and
heparin-coated circuits. The end result was that the heart-
lung machine had evolved and improved at a faster rate than
the technical skills of the surgeons performing beating-heart
surgery. The anticipated lower stroke rate, lower blood use,
and shorter hospital stays with OPCABG were not realized,
and the patency rates of our grafts were lower. This chapter
of evolving technology might be viewed by some as a step
backward. However, the technology of heart stabilization,
TABLE 1. A meta-analysis comparison of major cardiac
events after on-pump and off-pump CABG
No. of Patients
MI-stroke-death
composite end
point odds ratio
On-pump CABG 558 0.48 (P  .08)
Off-pump CABG 532
CABG, Coronary artery bypass grafting;MI, myocardial infarction. Adapted
with permission from Parolari et al.7the search for sutureless anastomosis, and minimally inva-
486 The Journal of Thoracic and Cardiovascular Surgery ● Marsive approaches has been a spin off of OPCABG. Although
great for selected patients, OPCABG will be considered one
of the stepping stones to the next evolution in coronary
surgery. The message to take away is that the current
proposed procedure might not be the answer to the current
problem, but it might serve as a building block.
Another example would be Heartport technology, which
was innovative and provided the foundation for our current
era of minimally invasive surgery. The mistake of Heartport
technology was not the technology per se but the marketing
strategy of introducing it as a revolutionary new technique
rather than as an adjunct to the surgeon. Today I view
robotic surgery as robotic assistance for established surgical
techniques of repairing mitral valves and performing coro-
nary revascularizations.
I would like to comment briefly on the leveling of the
playing field I spoke about earlier. Technology has ad-
vanced in all areas of the treatment of cardiovascular and
cardiothoracic diseases, with advances in imaging being
unsurpassed by any other field. In the future, this will
provide opportunities for us as cardiothoracic surgeons.
Imaging coronary arteries will not always be catheter based.
Patients will undergo magnetic resonance imaging angiog-
raphy or perhaps enhanced computed tomographic scan-
ning, which will provide a roadmap for coronary lesions.
Patients will view angiography as invasive, like invasive
surgical intervention, and will choose another less-invasive
way to have their heart disease diagnosed. Suddenly, the
playing field changes. The physician making the diagnosis
(radiologist-cardiologist) is no longer prescribing the ther-
apy. The apparent ease of immediately treating the coronary
lesions with the sheaths in the groin is gone. Patients will
weigh their various options and make evidence-based deci-
sions after gaining trust in the physician who is the mes-
senger of this information. I believe the convenience of the
therapy (“already in the catheterization laboratory sheaths in
place”) will be supplanted by evidence-based decisions.
As treating physicians, we have to be prepared to become
more involved with our patients as they try to sort out the
various options. If we are seen as unbiased with nothing to
gain but the patient’s health and interest, we will once again
be held in high regard and, consequently, our self-esteem as
TABLE 2. A randomized comparison of graft patency 3
months after on-pump and off-pump multivessel CABG
No. of patients
Patency of
grafts at 3 mo
On-pump CABG 50 98%* (127/130)
Off-pump CABG 54 88%* (114/130)
CABG, Coronary artery bypass grafting.
*P  .002.a profession will be restored.
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We are entering an exciting time of change and evolution in
our specialty. Many new techniques will be pioneered, and
our patients will benefit. More important, as trustees of our
specialty, we have to communicate this to future surgeons.
Our perceived enthusiasm for our specialty and its accom-
plishments will drive the next generation of surgeons. We
will determine the caliber of students selecting our spe-
cialty. Since the peak in 1996, the number of college grad-
uates choosing medicine is down by 26%.9 The number of
medical students to choose surgery is also down by 7%.10
To compound the problem further, the number of surgical
residents choosing our specialty is also down. Therefore, the
pool of potential candidates to become cardiothoracic sur-
geons has dramatically dropped since 1996.
The next challenge we face is the exposure of medical
students and surgical residents to our specialty. With the
80-hour work week, there are fewer general surgery resi-
dents on our services. The number of medical students
choosing to rotate on our specialty is also down because of
the decrease in emphasis of our specialty in the medical
school curricula. To overcome these hurdles, we have to
become excited once again by the specialty we practice. We
have to convincingly tell our students and residents of the
excitement of being a cardiothoracic surgeon. These poten-
tial students of our specialty will want to see our dedication
to our specialty and the passion with which we practice first
hand in operating rooms, research laboratories, and class-
rooms.
At USC, cardiothoracic surgery is seen as an exciting
specialty with a bright future. We have become part of the
medical school curriculum, with third- and fourth-year stu-
dents rotating on our service. To make the rotation a teach-
ing and learning experience, we have physician extenders to
help with histories and physical examinations, discharge
summaries, and chasing down laboratory values. This al-
lows the students to come to the operating room to observe
a patient having a robotic mitral valve repair. The general
surgery resident is afforded the same opportunity. It is this
group of students we have to impress to keep our specialty
interesting. By doing so, we will continue to attract the
brightest and best to our specialty.
I have often said that if I applied today, I could not get
into the cardiothoracic program at USC because of the
outstanding residents we have applying each year. Like
trout fishing, the highly prized trophy fish (resident) has
many lures to choose from. He waits until the very best
comes along before taking the bait. We have to present the
very best bait (an exciting and rewarding profession) if we
are going to attract the very best to our specialty. Once a
young resident expresses an interest, we have to foster their
enthusiasm. The entry point to our specialty is often the
The Journal of Thoracilaboratory during their general surgery training. The young
investigators in our laboratories at USC are exceptional. To
have exceptional laboratory experiences for our students,
we have to invest in faculty who will provide these expe-
riences. This requires protected time, incentives for writing
grants, and the rewards of a tenure track. This in turn is
again a great investment in the future of our specialty
because we are continuing the search for new and innova-
tive therapies and techniques for the benefit of our patients.
Once the student is involved with this activity, you will have
hooked the trophy fish. If we look to the future as one with
promise, our students will also be enthusiastic for the future
of cardiothoracic surgery.
I would like to leave you with a quote from the late
Charles Merriam, who was a political scientist. In 1934, he
stated the following: “The future belongs to those who fuse
intelligence with faith, and who with courage and determi-
nation grope their way forward from chance to choice, from
blind adaptation to creative evolution.”
It has been an immense honor to be president of The
Western Thoracic Surgical Association, and I thank you for
the opportunity.
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